Valuation: PFIZER

Market Cap 143B 143B 124B 116B 106B 200B 13,598B 204B 1,365B 535B 6,781B 536B 524B 22,366B P/E 2026 *
12.7x
P/E 2027 * 13.1x
Enterprise Value 192B 192B 167B 156B 143B 270B 18,303B 274B 1,837B 720B 9,127B 721B 705B 30,105B EV / Sales 2026 *
3.11x
EV / Sales 2027 * 3.13x
Free-Float
59.05%
Yield 2026 *
6.88%
Yield 2027 * 6.94%
Manager TitleAgeSince
Chief Executive Officer 64 2018-12-31
Director of Finance/CFO 60 2022-05-01
Chief Tech/Sci/R&D Officer - 2006-12-31
Director TitleAgeSince
Director/Board Member 68 2007-08-31
Director/Board Member 62 2013-09-26
Chairman 64 2019-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-2.39%-6.36%+47.10%+149.66% 1,024B
-0.76%-4.34%+52.04%+49.09% 618B
-2.33%-4.60%+25.55%+64.44% 443B
+0.68%-1.14%+38.47%+33.36% 349B
-1.66%-3.13%+32.18%+39.79% 297B
-8.96%-10.77%+3.57%+5.50% 264B
-1.37%-7.41%-2.10%-43.67% 209B
-1.63%+0.69%+27.62%+64.23% 208B
+0.72%+0.48%+15.88%+73.64% 162B
Average -1.54%-3.14%+26.70%+48.45% 397.08B
Weighted average by Cap. -0.98%-3.91%+34.56%+70.87%

Financials

2026 *2027 *
Net sales 61.74B 61.74B 53.66B 50.1B 45.99B 86.72B 5,885B 88.23B 591B 231B 2,935B 232B 227B 9,680B 59.37B 59.37B 51.6B 48.17B 44.22B 83.38B 5,659B 84.83B 568B 222B 2,822B 223B 218B 9,307B
Net income 10.63B 10.63B 9.24B 8.63B 7.92B 14.93B 1,013B 15.19B 102B 39.84B 505B 39.94B 39.05B 1,667B 10.28B 10.28B 8.93B 8.34B 7.66B 14.44B 980B 14.69B 98.35B 38.52B 489B 38.61B 37.76B 1,612B
Net Debt 49.36B 49.36B 42.9B 40.05B 36.77B 69.33B 4,705B 70.54B 472B 185B 2,346B 185B 181B 7,739B 43.17B 43.17B 37.52B 35.02B 32.15B 60.63B 4,114B 61.68B 413B 162B 2,052B 162B 159B 6,767B
Logo PFIZER
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (42.9%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (28%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (26.9%); - other (2.2%). The United States accounts for 59.2% of net sales.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A